ANAB AnaptysBio Inc.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Date	Price Target	Rating	Analyst
6/4/2025	$38.00	Neutral → Buy	H.C. Wainwright
2/4/2025	$25.00	Outperform	Wolfe Research
12/11/2024	$52.00 → $19.00	Buy → Neutral	H.C. Wainwright
12/2/2024		Buy → Neutral	BTIG Research
7/22/2024	$55.00	Buy	H.C. Wainwright
7/19/2024	$29.00 → $69.00	Neutral → Overweight	JP Morgan
4/16/2024	$47.00	Outperform	Leerink Partners
4/11/2024	$56.00	Overweight	Wells Fargo
3/12/2024	$20.00 → $34.00	Neutral → Outperform	Wedbush
2/26/2024	$55.00	Buy	BTIG Research

AnaptysBio Inc.

Recent Analyst Ratings for AnaptysBio Inc.

AnaptysBio Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Fenton Dennis M sold $72,270 worth of shares (3,015 units at $23.97), decreasing direct ownership by 38% to 4,965 units (SEC Form 4)

Director Renton Hollings sold $72,270 worth of shares (3,015 units at $23.97), decreasing direct ownership by 38% to 4,965 units (SEC Form 4)

Director Jain Rita converted options into 7,330 shares, increasing direct ownership by 162% to 11,864 units (SEC Form 4)

Director Fenton Dennis M converted options into 6,030 shares, increasing direct ownership by 309% to 7,980 units (SEC Form 4)

Director Marquet Magda converted options into 6,030 shares, increasing direct ownership by 155% to 9,930 units (SEC Form 4)

Director Orwin John A converted options into 6,030 shares, increasing direct ownership by 181% to 9,365 units (SEC Form 4)

Director Renton Hollings converted options into 6,030 shares, increasing direct ownership by 309% to 7,980 units (SEC Form 4)

Director Schmid John P. converted options into 6,030 shares, increasing direct ownership by 13% to 52,267 units (SEC Form 4)

Director Ware J. Anthony converted options into 6,030 shares, increasing direct ownership by 80% to 13,530 units (SEC Form 4)

Director Schmid John P. acquired $201,241 worth of shares (11,068 units at $18.18) (SEC Form 4)